Back to search results

BMS-986488 for Advanced Malignant Tumors

This study is looking at an experimental treatment called BMS-986488, either by itself or in combination with other drugs like Adagrasib, Cetuximab, or Nivolumab. The main goal is to see if these treatments are safe, tolerable, and can help fight advanced malignant tumors (cancers that have spread). Researchers will be carefully watching for any side effects. You might be able to join if you are at least 18 years old and have certain types of advanced solid tumors, including clear-cell renal cell carcinoma (kidney cancer), clear-cell ovarian cancer, non-small cell lung cancer, colorectal cancer, or pancreatic cancer. The study plans to enroll 437 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 437 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to approximately 100 days after your last dose of study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06764771

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~437 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:BMS-986488AdagrasibCetuximabNivolumab

At a glance

Recruiting sites
4 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Adverse Events (AEs)
Measured over Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
+4 more outcomes measured

Conditions

Advanced Malignant Tumors

Explore related trials

Colorectal CarcinomaLung Non-Small Cell CarcinomaMalignant Ovarian NeoplasmPancreatic Ductal AdenocarcinomaRenal Cell CarcinomaSolid NeoplasmGTPase KRas

Where it's being run

8 sites across 7 states
Quebec2
New Jersey1
Pennsylvania1
Tennessee1
Texas1
Queensland1
British Columbia1

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be ≥ 18 years of age.
Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Parts 2A, 1D, 2D: ccRCC.
Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
Participants must have measurable disease per RECIST v1.1.

Exclusion

Untreated central nervous system (CNS) metastases.
Leptomeningeal metastasis (carcinomatous meningitis).
Impaired cardiac function or clinically significant cardiac disease.
For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.

What this trial measures

  • Number of participants with Adverse Events (AEs)Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  • Number of participants with Serious AEs (SAEs)Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  • Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteriaFrom first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)
  • Number of participants with AEs leading to discontinuationUntil the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  • Number of deathsFrom time of informed consent up to 52 weeks after end of treatment visit